Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 08, 2018. The report serves as a Director Declaration in conformity with Listing Rule 9.6.14, notifying the market of a change in directorship.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding corporate governance rather than a financial results report.
Material Changes
The material change disclosed is the appointment of Dr. Jesse Goodman, a Non-Executive Director of GlaxoSmithKline plc, to the Board of Intellia Therapeutics, Inc., effective October 31, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the external director appointment.
Investor Verification Checklist
- Verify the effective date of Dr. Jesse Goodman's appointment to Intellia Therapeutics, Inc. (October 31, 2018).
- Confirm whether this new directorship creates any potential conflicts of interest with GSK's business operations.
- Review GSK's most recent Form 20-F or quarterly earnings release for actual financial performance data, as this filing does not contain financial metrics.